|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Transplanted organ | Immunosuppression Regimen | Steroid prophylaxis | Number of infusions | Duration of follow up (days) | Other non-hepatic irAEs | Outcome |
| 62 yo, M | Liver | Tacrolimus | Y | 1 | 8 | None | Unknown |
| 67 yo, m | Heart | Tacrolimus | N | 9 | 190 | None | Stable/remission of disease |
| 71 yo, M | Lung | Tacrolimus and prednisone | N | 2 | 460 | Pneumonitis | Stable/remission of disease |
| 83 yo, m | Kidney | Everolimus and prednisone | Y | 6 | 148 | Headache | Stable/remission of disease |
| 75 yo, m | Liver | Tacrolimus | N | 2 | 55 | None | Progression of disease |
| 77 yo, m | Liver | Tacrolimus | Y | 12 | 245 | None | Stable/remission of disease |
| 84 yo, f | Kidney | Tacrolimus and prednisone | N | 6 | 213 | None | Stable/remission of disease |
| 50 yo, m | Kidney | Everolimus and prednisone | Y | 15 | 383 | Rash | Progression of disease |

**Supplemental Table 1. Clinical characteristics and outcomes of solid organ transplants patients with cutaneous squamous cell carcinoma receiving cemiplimab monotherapy.**